116 related articles for article (PubMed ID: 9877245)
21. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
23. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
Bizzaro F; Falcetta F; D'Agostini E; Decio A; Minoli L; Erba E; Alessandro Peccatori F; Scanziani E; Colombo N; Zucchetti M; Bani MR; Ubezio P; Giavazzi R
Int J Cancer; 2018 Nov; 143(9):2187-2199. PubMed ID: 29752717
[TBL] [Abstract][Full Text] [Related]
24. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
[TBL] [Abstract][Full Text] [Related]
25. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
26. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
[TBL] [Abstract][Full Text] [Related]
27. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
28. Vinorelbine-induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma pretreated with carboplatin and paclitaxel.
Scalone S; Sorio R; Bortolussi R; Lombardi D; La Mura N; Veronesi A
Acta Oncol; 2004; 43(2):209-11. PubMed ID: 15163172
[No Abstract] [Full Text] [Related]
29. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
30. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Kubota K
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
[TBL] [Abstract][Full Text] [Related]
31. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.
Burbridge MF; Kraus-Berthier L; Naze M; Pierre A; Atassi G; Guilbaud N
Int J Oncol; 1999 Dec; 15(6):1155-62. PubMed ID: 10568822
[TBL] [Abstract][Full Text] [Related]
32. Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.
Köpf-Maier P
J Cancer Res Clin Oncol; 1987; 113(4):342-8. PubMed ID: 3036884
[TBL] [Abstract][Full Text] [Related]
33. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis.
Anderson K; Lawson KA; Simmons-Menchaca M; Sun L; Sanders BG; Kline K
Exp Biol Med (Maywood); 2004 Dec; 229(11):1169-76. PubMed ID: 15564444
[TBL] [Abstract][Full Text] [Related]
34. A Monte Carlo evaluation of dose enhancement by cisplatin and titanocene dichloride chemotherapy drugs in brachytherapy with photon emitting sources.
Yahya Abadi A; Ghorbani M; Mowlavi AA; Knaup C
Australas Phys Eng Sci Med; 2014 Jun; 37(2):327-36. PubMed ID: 24706342
[TBL] [Abstract][Full Text] [Related]
35. A controlled release system of titanocene dichloride by electrospun fiber and its antitumor activity in vitro.
Chen P; Wu QS; Ding YP; Chu M; Huang ZM; Hu W
Eur J Pharm Biopharm; 2010 Nov; 76(3):413-20. PubMed ID: 20854905
[TBL] [Abstract][Full Text] [Related]
36. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
37. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
38. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells.
Knick VC; Eberwein DJ; Miller CG
J Natl Cancer Inst; 1995 Jul; 87(14):1072-7. PubMed ID: 7616599
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
40. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.
Ahn JB; Ko WK; Lee JG; Shim KY; Jeung HC; Park JO; Yoo NC; Kim BS; Kim SK; Kim SK; Kim JH
Am J Clin Oncol; 2000 Dec; 23(6):622-8. PubMed ID: 11202811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
